These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25538378)

  • 1. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
    Haibo L; Xiaofang G; Chunming W; Jie Y; Guozhong C; Limei Z; Yong C; Yu F; Yingchun B; Wangjun Y; Junbo G
    Mediators Inflamm; 2014; 2014():963096. PubMed ID: 25538378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare-metal stent compared to drug-eluting stent implantation.
    Hudzik B; Szkodzinski J; Pietka-Rzycka A; Danikiewicz A; Wojnar R; Lekston A; Polonski L; Zubelewicz-Szkodzinska B
    J Interferon Cytokine Res; 2013 May; 33(5):280-4. PubMed ID: 23414296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation.
    Ljuca F; Hadžiefendić B; Jahić E; Tihić N; Lukić S
    Saudi Med J; 2019 Dec; 40(12):1202-1208. PubMed ID: 31828271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention.
    Wang Z; Sato A; Akiyama D; Kimura T; Tajiri K; Hoshi T; Sakai S; Koike A; Miyauchi T; Aonuma K
    Life Sci; 2014 Jan; 95(1):40-4. PubMed ID: 24333560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction.
    Kimura S; Inagaki H; Haraguchi G; Sugiyama T; Miyazaki T; Hatano Y; Yoshikawa S; Ashikaga T; Isobe M
    Circ J; 2014; 78(1):159-69. PubMed ID: 24132243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris.
    Kimura S; Sugiyama T; Hishikari K; Nakagama S; Nakamura S; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Sagawa Y; Kojima K; Ohtani H; Hikita H; Takahashi A
    Atherosclerosis; 2020 Jan; 292():127-135. PubMed ID: 31805452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention.
    Guo R; Li Y; Wen J; Li W; Xu Y
    Cardiology; 2014; 129(3):178-88. PubMed ID: 25323314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation.
    Hudzik B; Danikiewicz A; Szkodzinski J; Polonski L; Zubelewicz-Szkodzinska B
    Eur Cytokine Netw; 2014; 25(3):41-5. PubMed ID: 25373851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent.
    Park JB; Kang DY; Yang HM; Cho HJ; Park KW; Lee HY; Kang HJ; Koo BK; Kim HS
    Eur Heart J; 2013 Mar; 34(12):920-31. PubMed ID: 23242189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation.
    Li JJ; Yan HB; Xiang XP; Qin XW; Zhang CY
    Cardiovasc Drugs Ther; 2009 Apr; 23(2):137-43. PubMed ID: 19016317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina.
    Mostowik M; Siniarski A; Gołębiowska-Wiatrak R; Nessler J; Gajos G
    Adv Clin Exp Med; 2015; 24(6):979-85. PubMed ID: 26771969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
    Akgul O; Baycan OF; Bulut U; Somuncu MU; Pusuroglu H; Ozyilmaz S; Gul M; Demir AR; Yılmaz E; Yazan S; Kokturk U; Cetin I; Uyarel H
    Coron Artery Dis; 2015 Nov; 26(7):592-7. PubMed ID: 26061437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease.
    Hollan I; Bottazzi B; Cuccovillo I; Førre ØT; Mikkelsen K; Saatvedt K; Almdahl SM; Mantovani A; Meroni PL;
    Arthritis Care Res (Hoboken); 2010 Mar; 62(3):378-85. PubMed ID: 20391484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major adverse cardiovascular events after drug-eluting stent implantation in patients with single chronic total occlusion: a single-center registry.
    Gilis-Siek N; Fijalkowski M; Jaguszewski M; Targonski R; Strozyk A; Cackowska M; Masiewicz E; Skarzynski P; Burakowski S; Chmielecki M; Lewicki L; Dubaniewicz W; Gruchala M; Ciecwierz D; Rynkiewicz A
    J Invasive Cardiol; 2013 Nov; 25(11):567-72. PubMed ID: 24184890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of direct sirolimus-eluting stent implantation on the early systemic inflammatory response compared with complementary stent implantation.
    Li JJ; Zhang YP; Wang C; Gao LJ; Qin XW; Xu B; Chen JL; Yang YJ; Gao RL
    Coron Artery Dis; 2009 Jan; 20(1):65-70. PubMed ID: 19018239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.